NCT03745989 2023-07-27
MK-8353-014
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
3 trialsNCT00970359 2017-04-12
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01605916 2016-10-21
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
AstraZeneca
Phase 1 Completed